Logo only.png

Phages for a healthier world

We develop innovative bacteriophage-based products to help the world's most vulnerable communities prosper.

 

PhagePro is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities. We are a discovery-driven venture spun out of the Camilli Lab at Tufts University School of Medicine in Boston. PhagePro aims to use bacteriophages, which are viruses that specifically target and kill bacteria, to prevent bacterial infections.

 

 
 

About

Find out about our organization, mission, and our projects.

Learn More →

Contact us

Interested in finding out more?  Contact us with your questions and comments!

E-mail Us →


PhagePro is hiring a Principal Scientist!

The Opportunity

PhagePro is looking for a Principal Scientist to carry forth our research for our phage-based cholera intervention as we scale-up our studies in preparation for clinical trials. We are a flat and dynamic organization, and the Principal Scientist is crucial to our success in the field.  The position is for one year, and it is located at PhagePro’s lab space at the Tufts Launchpad in Boston, MA.

Key Responsibilities

  • Support the translational development of phage-based interventions using molecular biology and microbiology techniques 

  • Problem-solve through literature searches and logical experimental design

  • Generate detailed lab notebooks 

  • Present scientific data at lab meetings and conferences

  • Write manuscripts for peer review

  • Manage early-stage lab inventory

  • Work collaboratively on a team

  • Attend team meetings

  • Contribute to scientific writing on external documents

  • Work collaboratively with external partners

Required Skills and Qualifications

  • Extensive bench experience in microbiology, virology, immunology, and/or related field

  • Strong analytical and quantitative skills

  • Demonstrated strong technical writing

  • Authorized to work in the U.S.

  • Ability to work well independently as well as with a team 

  • Excellent communication skills

  • Self-motivated learner

  • Ability to learn and act on dynamic information

  • Ability to multitask efficiently 

  • Excellent organizational skills and attention to detail

Preferred Experience

  • Advanced degree

  • Experience working with bacteriophages and/or bacteria

  • Industry experience

  • Knowledge of healthcare settings in low- and middle-income countries

  • First-author publication(s)

Our Culture

You are a good fit for our team if you are:

  • Passionate and motivated by global health disparities

  • An advocate for creating a diverse and inclusive work environment

  • Open-minded and collaborative

  • Driven by innovation

  • Intellectually curious

  • Able to operate effectively and efficiently with little oversight

Please send your resume and cover letter to info@phageproinc.com. We look forward to getting to know you.


PhagePro’s Founding CEO Dr. Minmin Yen Named To MIT Technology Review’s 2018 Innovators Under 35 List

 

BOSTON, MA, UNITED STATES – June 27, 2018:  Today, PhagePro announced Dr. Minmin Yen has been named to MIT Technology Review’s prestigious annual list of Innovators Under 35 as a humanitarian. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world.

 

Dr. Yen researched the use of phages as an intervention for cholera during her thesis work in the Camilli Lab at Tufts University, resulting in publications in Nature Communications and eLife. As a biological engineering undergraduate at MIT, she trained with Professors David Schauer and Darrell Irvine and researched oral vaccine delivery. Passionate about developing innovative solutions for infectious diseases, Dr. Yen was awarded the Howard Hughes Medical Institute MERGE-ID fellowship, which focused on translating bench science to clinical applications, for her graduate education. During her thesis research, Dr. Yen has traveled to Haiti to study the cholera epidemic, where she witnessed the need for innovative healthcare solutions. She also served as the U.S. representative in the Young Leaders Circle for three years as a part of American Society of Microbiology’s initiative to address the needs of international early-stage scientists. Dr. Yen is currently a Master’s in Public Health candidate at Boston University, with a focus in global health and program management. Her work with PhagePro has also recently been recognized at the inaugural MIT Women’s unConference, where she won first place in the startup competition.

 

Gideon Lichfield, editor-in-chief of MIT Technology Review, said: “MIT Technology Review inherently focuses on technology first - the breakthroughs and their potential to disrupt our lives. Our annual Innovators Under 35 list is a chance for us to honor the outstanding people behind those technologies. We hope these profiles offer a glimpse into what the face of technology looks like today as well as in the future.”

 

Learn more about this year’s honorees on the MIT Technology Review website here and in the July/August print magazine, which will hit newsstands worldwide on July 3. The honorees are also invited to appear in person at the upcoming EmTech MIT conference, MIT Technology Review’s flagship event exploring future trends and technologies that will impact the global economy, happening September 11-14, 2018 in Cambridge, Massachusetts.

 

PhagePro is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities. Founded in 2016, it is a discovery-driven venture spun out of the Camilli Lab at Tufts University School of Medicine in Boston. PhagePro aims to use bacteriophages, which are viruses that specifically target and kill bacteria, to prevent bacterial infections. With the unmitigated rise of antibiotic resistance and the known negative consequences of gut dysbiosis caused by broad-spectrum antibiotics, bacteriophages provide a side effect-free alternative for preventing disease in clinical and community contexts. The first product, ProphaLytic-VC, is an orally administered bacteriophage cocktail that specifically kills the bacteria that cause cholera and will be used as an intervention for household members of cholera patients in vulnerable communities.

 

About MIT Technology Review

Founded at the Massachusetts Institute of Technology in 1899, MIT Technology Review is a world-renowned, independent media company whose insight, analysis, reviews, interviews and live events explain the commercial, social and political impact of new technologies. MIT Technology Review derives its authority from the world's foremost technology institution and from its editors' deep technical knowledge, capacity to see technologies in their broadest context, and unequaled access to leading innovators and researchers. MIT Technology Review’s mission is to bring about better-informed and more conscious decisions about technology through authoritative, influential and trustworthy journalism. Subscribe. Follow: Twitter, Facebook, LinkedIn, Google+, Instagram.

 

###

 

Minmin Yen, Ph.D.

Founding CEO at PhagePro

myen@phageproinc.com

 

Media Contact:

Meredith Chiricosta

BIGfish Communications for MIT Technology Review

press@technologyreview.com

617-713-3800